For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
AMYLOID
Study Name: ION-682884-CS2 (Amyloid)
Study Objective: A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled
Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)
Key Inclusion Criteria:
A) prior hospitalization for HF, which may include hospitalization for arrhythmia or pacemaker/ICD (implantable cardioverter defibrillator) placement, OR
B) symptoms and signs of volume overload or elevated intracardiac pressure that either requires or required treatment with diuretics for clinical stabilization
Key Exclusion Criteria:
4 weeks prior to or during Screening
completed prior to Study Day 1
PI: Parag Goyal, MD (646) 962 5555
RC: Astrid Carmona (212) 746 2623